EFFECTS OF RECOMMENDED DRUGS USED IN THE TREATMENT OF COVID-19 INFECTION ON LIPID PROFILE IN ALBINO WISTAR RATS
Faculty
Department
Year of Publication
Publication Type
Abstract
The SARS-CoV-2 virus is the infectious agent that causes COVID-19, commonly
referred to as coronavirus illness. Chloroquine (CQ), Hydroxylchloroquine (HCQ),
Lopinavor/Retinavir (L/R), and other medications were tested for treating COVID-19 infection. Alcohol or phosphate functional group molecules are uncommon in lipids, which are esters of fatty acids that are soluble in organic solvents but insoluble in water. Triglycerides, HDL cholesterol, LDL cholesterol, and total cholesterol make up the lipid profile. The aim of the thesis is to ascertain and assess how prescribed medications for the management of COVID-19 infection affect albino rats' lipid levels. In total, 60 albino wistar rats were employed in this investigatigation. 6 were used as negative controls (given with water and feed only), while 54 were used as positive controls (administered with the medications). On the 29th day, blood samples were collected from the albino wistar rats into plain containers and serum were obtained for laboratory analysis of the lipid profile indices.. Version 27 of SPSS (Statistical Package for Social Sciences) was used to analyze the study's data. For both tests and controls, the Standard Error of Mean was expressed as mean ± S.E.M. Additionally, an ANOVA was used to compare the results at a 95% confidence interval (P<0.05). Notably, the combination treatment containing Hydroxylchloroquine (HCQ), Ivermectin (IV), L/R (Lopinavir/Retinavir), Azithromycin (AZI), Zinc (Zn), and Selenium (Se) led to a significant decrease in HDL_c levels (P<0.05) and weight (P<0.05) compared to the control group. This was in addition to the notable reduction in total cholesterol (TC) levels (P <0.05) that HCQ showed. Additionally, compared to the control group, Chloroquine (CQ) showed significantly lower cardiac risk ratios (P<0.05) and atherogenic coefficients (P<0.05), suggesting a possible decrease in cardiovascular risk and atherogenic potential. Additionally, compared to the control group, the ydroxychloroquine (HCQ) treatment group showed significantly decreased cardiac risk ratios (P<0.05) and atherogenic coefficients (P<0.05). Nevertheless, the combination therapy with CQ, IV, L/R, AZI, Zn, and Se showed noticeably greater atherogenic coefficients and cardiac risk ratios. In conclusion, the study elucidated the various effects of the drugs on lipid profile, weight, cardiac risk ratio, and atherogenic coefficient. However, while both CQ and HCQ treatments led to significant weight gain, contrary to some findings, their mechanisms of action on weight regulation remain complex and warrant further investigation.
referred to as coronavirus illness. Chloroquine (CQ), Hydroxylchloroquine (HCQ),
Lopinavor/Retinavir (L/R), and other medications were tested for treating COVID-19 infection. Alcohol or phosphate functional group molecules are uncommon in lipids, which are esters of fatty acids that are soluble in organic solvents but insoluble in water. Triglycerides, HDL cholesterol, LDL cholesterol, and total cholesterol make up the lipid profile. The aim of the thesis is to ascertain and assess how prescribed medications for the management of COVID-19 infection affect albino rats' lipid levels. In total, 60 albino wistar rats were employed in this investigatigation. 6 were used as negative controls (given with water and feed only), while 54 were used as positive controls (administered with the medications). On the 29th day, blood samples were collected from the albino wistar rats into plain containers and serum were obtained for laboratory analysis of the lipid profile indices.. Version 27 of SPSS (Statistical Package for Social Sciences) was used to analyze the study's data. For both tests and controls, the Standard Error of Mean was expressed as mean ± S.E.M. Additionally, an ANOVA was used to compare the results at a 95% confidence interval (P<0.05). Notably, the combination treatment containing Hydroxylchloroquine (HCQ), Ivermectin (IV), L/R (Lopinavir/Retinavir), Azithromycin (AZI), Zinc (Zn), and Selenium (Se) led to a significant decrease in HDL_c levels (P<0.05) and weight (P<0.05) compared to the control group. This was in addition to the notable reduction in total cholesterol (TC) levels (P <0.05) that HCQ showed. Additionally, compared to the control group, Chloroquine (CQ) showed significantly lower cardiac risk ratios (P<0.05) and atherogenic coefficients (P<0.05), suggesting a possible decrease in cardiovascular risk and atherogenic potential. Additionally, compared to the control group, the ydroxychloroquine (HCQ) treatment group showed significantly decreased cardiac risk ratios (P<0.05) and atherogenic coefficients (P<0.05). Nevertheless, the combination therapy with CQ, IV, L/R, AZI, Zn, and Se showed noticeably greater atherogenic coefficients and cardiac risk ratios. In conclusion, the study elucidated the various effects of the drugs on lipid profile, weight, cardiac risk ratio, and atherogenic coefficient. However, while both CQ and HCQ treatments led to significant weight gain, contrary to some findings, their mechanisms of action on weight regulation remain complex and warrant further investigation.
Supervisor(s)
co-supervisor